Axonics, Inc. Profile Avatar - Palmy Investing

Axonics, Inc.

Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulation (SNM) systems. The company's SNM systems are used to treat patients with overactive bladder, including urinary urge incontinence and u…
Medical - Devices
US, Irvine [HQ]

Ratios

8 Sheets · Starting from 2023
Margins, Growth Rates In %
Ratio 2016 2017 2018 2019 2020 2021 2022 2023
Profitability
Gross Margin
- - 7.94 49.65 53.04 60.15 64.18 72.22 72.46
Profit Margin
- - -14,097.05 -4,594.48 -578.40 -49.24 -44.41 -21.81 -1.66
Operating Margin
- - -14,185.62 -4,545.54 -583.21 -48.20 -37.38 -15.49 -1.29
EPS Growth
- - -2.11 -378.35 39.66 47.14 -25.68 31.18 90.63
Return on Assets (ROA)
-160.29 -61.41 -18.90 -36.36 -16.05 -14.61 -9.05 -0.85
Return on Equity (ROE)
35.20 27.19 -22.67 -43.68 -19.11 -16.60 -10.47 -0.95
Return on Invested Capital (ROIC)
35.59 27.39 -19.27 -38.68 -16.86 -13.81 -7.01 -0.49
Solvency
Equity Ratio
-400 -200 - - - - - - - - - - - -
Debt/Assets
2.78 0.46 13.68 11.55 9.22 1.90 1.38 3.84
Debt/Equity
-0.61 -0.20 16.41 13.87 10.98 2.16 1.60 4.33
Debt/EBITDA
47.14 140.49 240.19 187.69 395.55 350.11 824.32 -889.84
Debt/Capitalization
-0.61 -0.20 14.10 12.18 9.89 2.11 1.57 4.15
Interest Debt per Share USD
0.02 0.01 3.55 0.97 0.90 0.41 0.25 0.58
Debt Growth
- - -55.23 17,318.10 7.98 24.25 -66.97 -12.49 202.92
Liquidity
Current Ratio
587.80 1,119.27 2,808.56 1,759.16 717.89 1,195.91 712.79 1,072.60
Quick Ratio
552.77 1,014.44 2,683.05 1,591.90 567.95 930.18 616.16 877.87
Cash Ratio
552.77 1,014.44 1,669.88 1,421.77 527.96 822.09 366.06 228.77
Operating Cash Flow Ratio
-1,100 -700 -500 -600 -100 -100 - - - -
Turnover
Inventory Turnover
- - 7.65 9.69 41.45 70.48 99.42 136.35 126.21
Receivables Turnover
- - - - 165.57 175.40 610.48 620.75 610.71 640.04
Payables Turnover
- - 7.30 10.36 110.34 416.92 843.64 838.34 546.77
Asset Turnover
- - 0.44 0.41 6.29 32.59 32.90 41.51 50.89
Coverage
Interest Coverage
- - - - -2,392.93 -3,490.65 -2,868.73 -907.54 -1,741.37 -755.13
Asset Coverage
3,100 20,000 700 800 1,000 3,900 5,500 2,100
Cash Flow Coverage (CFGR)
-5,749.44 -13,463.53 -133.42 -328.71 -265.48 -454.08 35.00 -7.30
EBITDA Coverage
- - - - -2,300 -3,300 -2,800 -800 -1,100 1,300
Dividend Coverage
- - - - - - - - - - - - - - - -
Time Interest Earned (TIE)
- - - - - - - - - - - - - - - -
Market Prospects
Dividend Yield
- - - - - - - - - - - - - - - -
Earnings Yield
-6.32 -6.47 -30.72 -10.10 -2.98 -3.32 -2.05 -0.20
Price/Earnings (P/E)
-1,582.16 -1,544.75 -325.51 -990.30 -3,361.76 -3,012.54 -4,889.91 -50,169.84
Price/Book (P/B)
-556.95 -420.04 73.80 432.56 642.42 499.97 512.01 479.06
Price/Sales (P/S)
- - 217,763.87 14,955.65 5,727.93 1,655.18 1,337.87 1,066.55 833.66
Price/Cash Flow (P/CF)
-1,588.13 -1,535.14 -337.06 -948.55 -2,204.52 -5,098.82 91,481.68 -151,505.03
End of AXNX's Analysis
CIK: 1603756 CUSIP: 05465P101 ISIN: US05465P1012 LEI: - UEI: -
Secondary Listings
AXNX has no secondary listings inside our databases.